Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FZX57
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,679
Award facts
- Contract value 100% obligated
- $5,678.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order contract on August 1, 2025, by the Defense Logistics Agency (DLA) for the supply of Nucala 100 mg/ml auto-injectors. The contract is valued at $5,678.70 and carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The award was made without set-aside designation, and performance will occur at the vendor's facility in Park Ridge, Illinois. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle that enables the agency to procure an extensive portfolio of pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide through November 2026.
Nucala (mepolizumab) is a biologic medication used in the treatment of eosinophilic asthma and other eosinophil-mediated conditions, and this delivery order fulfills a specific medical supply requirement for military health facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing contracts with the DLA to deliver branded pharmaceuticals, biologics, specialty medications, and medical consumables to support DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB25FZX57?
SPE2DB25FZX57 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 1, 2025.
How much is contract SPE2DB25FZX57 worth?
The government has obligated $5,679 on SPE2DB25FZX57.
Is contract SPE2DB25FZX57 an order under another contract?
Yes. SPE2DB25FZX57 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZX57 competed?
The extent of competition for SPE2DB25FZX57 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award